These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
536 related articles for article (PubMed ID: 26717039)
1. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis. Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039 [TBL] [Abstract][Full Text] [Related]
2. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
3. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294 [TBL] [Abstract][Full Text] [Related]
4. Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signaling. Xiong S; Klausen C; Cheng JC; Zhu H; Leung PC Oncotarget; 2015 Oct; 6(31):31659-73. PubMed ID: 26384307 [TBL] [Abstract][Full Text] [Related]
5. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795 [TBL] [Abstract][Full Text] [Related]
7. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
8. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897 [TBL] [Abstract][Full Text] [Related]
9. Microenvironment involved in FPR1 expression by human glioblastomas. Boer JC; van Marion DM; Joseph JV; Kliphuis NM; Timmer-Bosscha H; van Strijp JA; de Vries EG; den Dunnen WF; Kruyt FA; Walenkamp AM J Neurooncol; 2015 May; 123(1):53-63. PubMed ID: 25894595 [TBL] [Abstract][Full Text] [Related]
10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
11. Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth. Zhu Y; Zhao K; Prinz A; Keyvani K; Lambertz N; Kreitschmann-Andermahr I; Lei T; Sure U Neuro Oncol; 2016 Apr; 18(4):538-48. PubMed ID: 26254477 [TBL] [Abstract][Full Text] [Related]
12. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model. Wei JW; Cui JQ; Zhou X; Fang C; Tan YL; Chen LY; Yang C; Liu M; Kang CS Cancer Lett; 2016 Sep; 380(1):1-9. PubMed ID: 27317648 [TBL] [Abstract][Full Text] [Related]
13. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250 [TBL] [Abstract][Full Text] [Related]
14. EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells. Yang C; Li YS; Wang QX; Huang K; Wei JW; Wang YF; Zhou JH; Yi KK; Zhang KL; Zhou BC; Liu C; Zeng L; Kang CS Cancer Lett; 2017 Sep; 403():119-127. PubMed ID: 28634045 [TBL] [Abstract][Full Text] [Related]
15. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII. Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856 [TBL] [Abstract][Full Text] [Related]
16. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604 [TBL] [Abstract][Full Text] [Related]
19. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Feldkamp MM; Lala P; Lau N; Roncari L; Guha A Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712 [TBL] [Abstract][Full Text] [Related]
20. Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro. Lan Q; Wang A; Cheng Y; Mukasa A; Ma J; Hong L; Yu S; Sun L; Huang Q; Purow B; Li M Oncotarget; 2016 Mar; 7(9):9680-91. PubMed ID: 26848767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]